The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus

The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus

The first human glucagon-like peptide-1 analog (liraglutide) was registered in Russia in May 2010. This review contains data on the results of randomizedclinical studies of this preparation applied to the treatment of patients with DM2 as monotherapy and in combination with traditional hypoglycemica...

Full description

Bibliographic Details
Main Author:	Marina Vladimirovna Shestakova
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2010-09-01
Series:	Сахарный диабет
Subjects:	incretins human glucagon-like peptide-1 (glp-1) liraglutide victoza
Online Access:	https://www.dia-endojournals.ru/jour/article/view/5497

Similar Items

Glucagon-like peptide-1 analogues: An overview
by: Vishal Gupta
Published: (2013-01-01)

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes
by: Fujishima Yuya, et al.
Published: (2012-09-01)

Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
by: Campbell RK, et al.
Published: (2010-07-01)

Incretins role in Latent autoimmune diabetes of adults pathogenesis, the possibility of therapy with combination of glucagon-like peptide-1 agonist (GLP-1) and insulin.
by: Iuliia V. Silko, et al.
Published: (2016-07-01)

Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
by: Syed Faizan Mehdi, et al.
Published: (2023-05-01)

Glucagon Like Peptide 1 and Evidence Around Diabetes Specific Nutrition
by: ANSHU JOSHI, et al.
Published: (2019-06-01)

Physiology and pharmacology of glucagon-like peptide-1 receptor
by: D. V. Kurkin, et al.
Published: (2024-01-01)

The Impact of Glucagon-like Peptide 1 Receptor Agonists on Obstructive Sleep Apnoea: A Scoping Review
by: Khang Duy Ricky Le, et al.
Published: (2024-01-01)

First GLP-1 analog liraglutide: the result of clinical trails on efficacy
by: Alexander Sergeevich Ametov, et al.
Published: (2011-12-01)

Glucagon-like Peptide-1 Receptor Agonists: Are They as Good as They Seem? A Systematic Review of Severe Adverse Effects
by: Pranjal Sharma, et al.
Published: (2024-08-01)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
by: Seungah Lee, et al.
Published: (2017-03-01)

GLP-1 Analog Liraglutide Improves Vascular Function in Polymicrobial Sepsis by Reduction of Oxidative Stress and Inflammation
by: Johanna Helmstädter, et al.
Published: (2021-07-01)

Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
by: Gagik R. Galstyan, et al.
Published: (2017-10-01)

The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury
by: Anja Harej Hrkać, et al.
Published: (2024-10-01)

Diabetes and obesity. The role of agonists glucagon-like peptide-1 of in the treatment of type 2 diabetes
by: Nina A. Petunina, et al.
Published: (2018-09-01)

Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics
by: A. Delgado, et al.
Published: (2021-04-01)

Liraglutide; A New Hope for Obese Diabetics
by: Ajeet Kumar, et al.
Published: (2020-12-01)

Relevance of Autophagy Induction by Gastrointestinal Hormones: Focus on the Incretin-Based Drug Target and Glucagon
by: Keizo Kanasaki, et al.
Published: (2019-05-01)

Prognostic factors for the carbohydrate metabolism normalization in patients with type 2 diabetes mellitus and obesity using liraglutide 3.0 mg per day
by: Igor A. Sklyanik, et al.
Published: (2021-10-01)

Anatomical and Functional Characterization of Central Amygdala Glucagon-Like Peptide 1 Receptor Expressing Neurons
by: Ningxiang Zeng, et al.
Published: (2021-12-01)

Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?
by: C. Meurot, et al.
Published: (2022-01-01)

Glucagon-like peptide-1 attenuates diabetes-associated osteoporosis in ZDF rat, possibly through the RAGE pathway
by: Yanzhen Cheng, et al.
Published: (2022-05-01)

Renal effects of glucagon-like peptide receptor agonists in patients with type 1 diabetes mellitus
by: O K Vikulova, et al.
Published: (2018-06-01)

Efficacy and Safety of Glucagon Like Peptide-1 Receptor Agonism Based Therapies in Obstructive Sleep Apnoea: A Systematic Review and Meta-Analysis
by: Deep Dutta, et al.
Published: (2025-01-01)

Secretion of glucagon, GLP-1 and GIP may be affected by circadian rhythm in healthy males
by: Dorte B. Zilstorff, et al.
Published: (2024-03-01)

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
by: Enrique Z. Fisman, et al.
Published: (2021-11-01)

Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review
by: Alorfi NM, et al.
Published: (2022-08-01)

Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain
by: Simon C. Cork, et al.
Published: (2015-10-01)

Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus
by: Alexander C. Martins, et al.
Published: (2024-04-01)

The associations of incretin hormone concentration with gestational diabetes mellitus
by: Tatiana V. Saprina, et al.
Published: (2016-05-01)

Obezitenin Medikal Tedavisinde Liraglutide Etkinliğinin Araştırılması
by: Murat Kose, et al.
Published: (2023-09-01)

Glucagon-Like Peptide-1
by: Joel P. Giblett, BM, BSc, et al.
Published: (2016-06-01)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
by: Knop FK, et al.
Published: (2010-05-01)

Evaluation of Glucagon-Like Peptide 1 (GLP-1) Levels and Oxidative Stress in Preterm Infants
by: E Abbasi, et al.
Published: (2022-03-01)

The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis
by: Hanieh Radkhah, et al.
Published: (2025-02-01)

Human islets contain a subpopulation of glucagon-like peptide-1 secreting α cells that is increased in type 2 diabetes
by: Scott A. Campbell, et al.
Published: (2020-09-01)

Incretin-Based Multi-Agonist Peptides Are Neuroprotective and Anti-Inflammatory in Cellular Models of Neurodegeneration
by: Katherine O. Kopp, et al.
Published: (2024-07-01)

Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function
by: Young-Kook Kim, et al.
Published: (2020-08-01)

Gglucagon-like peptide-1 analogue liraglutide (Saxenda®): mechanism of action, efficacy for the treatment of obesity
by: Tatiana I. Romantsova
Published: (2018-04-01)

Clinical Application of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
by: Young Min Cho, et al.
Published: (2013-12-01)